ParkinsonCanadaV1, Main, Exploration, bibRecord, 001D36

CHANGES OF AMPA RECEPTORS IN MPTP MONKEYS WITH LEVODOPA-INDUCED DYSKINESIAS

Identifieur interne : 001D36 ( Main/Exploration ); précédent : 001D35; suivant : 001D37

CHANGES OF AMPA RECEPTORS IN MPTP MONKEYS WITH LEVODOPA-INDUCED DYSKINESIAS

Auteurs : B. Ouattara [Canada] ; D. Hoyer [Suisse] ; L. Gregoire [Canada] ; M. Morissette [Canada] ; F. Gasparini [Suisse] ; B. Gomez-Mancilla [Suisse] ; T. Di Paolo [Canada]

Source :

Neuroscience [ 0306-4522 ] ; 2010.

RBID : Pascal:10-0396916

Descripteurs français

Pascal (Inist)
- Récepteur AMPA, Neurotoxine, Lévodopa, Glutamate, Cabergoline, Dopamine, Maladie de Parkinson, Singe, MPTP.
Wicri :
- topic : Singe.

English descriptors

KwdEn :
- AMPA receptor, Cabergoline, Dopamine, Glutamate, Levodopa, Monkey, Neurotoxin, Parkinson disease.

Abstract

Overactivity of glutamate neurotransmission is suspected to be implicated in Parkinson's disease and levodopa-induced dyskinesia. The fast glutamatergic transmission in the striatum from the cortex is mediated mainly by non-N-methyl-D-aspartate (non-NMDA) receptors. Animal models of Parkinson's disease reveal conflicting data concerning striatal glutamate AMPA receptors. The present study thus sought to shed light on the relationship of striatal AMPA receptors to the development of levodopa-induced dyskinesia. [³H]Ro 48-8587, a highly potent and selective-specific antagonist ligand for AMPA receptors, was used to investigate, by autoradiography, striatal AMPA receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys treated for 1 month with levodopa alone, levodopa+CI-1041 (NMDA receptor antagonist) or levodopa+cabergoline (D2 receptor agonist). Levodopa-treated MPTP monkeys developed dyskinesias while those that received levodopa+CI-1041 or levodopa+cabergoline did not. In the anterior caudate nucleus and putamen, specific binding of [³H]Ro 48-8587 was reduced in all MPTP-treated monkeys compared to control monkeys, but no significant effect of MPTP was measured in the posterior striatum. In dyskinetic monkeys, specific binding of [³H]Ro 48-8587 was elevated in subregions of the posterior caudate nucleus and putamen as compared to saline-treated MPTP monkeys. Levodopa+CI-1041 treatment left unchanged specific binding of [³H]Ro 48-8587 whereas levodopa+cabergoline treatment reduced it in subregions of the posterior caudate nucleus and putamen compared to control and levodopa-treated MPTP monkeys. Specific binding of [³H]Ro 48-8587 was low in the globus pallidus and remained unchanged following both lesion and treatments. In conclusion, the elevated values of AMPA receptors in dyskinetic monkeys (and their prevention through treatments) were only observed in subregions of the striatum.

Affiliations:

Canada, Suisse

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000407
to stream PascalFrancis, to step Curation: 000870
to stream PascalFrancis, to step Checkpoint: 000384
to stream Main, to step Merge: 001E74
to stream Main, to step Curation: 001D36

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">CHANGES OF AMPA RECEPTORS IN MPTP MONKEYS WITH LEVODOPA-INDUCED DYSKINESIAS</title>
<author><name sortKey="Ouattara, B" sort="Ouattara, B" uniqKey="Ouattara B" first="B." last="Ouattara">B. Ouattara</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Genomic Research Center, Centre Hospitalier Universitaire de Québec (CHUQ), Pavilion CHUL and Faculty of Pharmacy, Laval University</s1>
<s2>QC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hoyer, D" sort="Hoyer, D" uniqKey="Hoyer D" first="D." last="Hoyer">D. Hoyer</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neuroscience Research, Novartis Institutes for BioMedical Research</s1>
<s2>4002 Basel</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>4002 Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L." last="Gregoire">L. Gregoire</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Genomic Research Center, Centre Hospitalier Universitaire de Québec (CHUQ), Pavilion CHUL and Faculty of Pharmacy, Laval University</s1>
<s2>QC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Genomic Research Center, Centre Hospitalier Universitaire de Québec (CHUQ), Pavilion CHUL and Faculty of Pharmacy, Laval University</s1>
<s2>QC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gasparini, F" sort="Gasparini, F" uniqKey="Gasparini F" first="F." last="Gasparini">F. Gasparini</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neuroscience Research, Novartis Institutes for BioMedical Research</s1>
<s2>4002 Basel</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>4002 Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gomez Mancilla, B" sort="Gomez Mancilla, B" uniqKey="Gomez Mancilla B" first="B." last="Gomez-Mancilla">B. Gomez-Mancilla</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neuroscience Research, Novartis Institutes for BioMedical Research</s1>
<s2>4002 Basel</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>4002 Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Genomic Research Center, Centre Hospitalier Universitaire de Québec (CHUQ), Pavilion CHUL and Faculty of Pharmacy, Laval University</s1>
<s2>QC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0396916</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0396916 INIST</idno>
<idno type="RBID">Pascal:10-0396916</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000407</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000870</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000384</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000384</idno>
<idno type="wicri:doubleKey">0306-4522:2010:Ouattara B:changes:of:ampa</idno>
<idno type="wicri:Area/Main/Merge">001E74</idno>
<idno type="wicri:Area/Main/Curation">001D36</idno>
<idno type="wicri:Area/Main/Exploration">001D36</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">CHANGES OF AMPA RECEPTORS IN MPTP MONKEYS WITH LEVODOPA-INDUCED DYSKINESIAS</title>
<author><name sortKey="Ouattara, B" sort="Ouattara, B" uniqKey="Ouattara B" first="B." last="Ouattara">B. Ouattara</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Genomic Research Center, Centre Hospitalier Universitaire de Québec (CHUQ), Pavilion CHUL and Faculty of Pharmacy, Laval University</s1>
<s2>QC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hoyer, D" sort="Hoyer, D" uniqKey="Hoyer D" first="D." last="Hoyer">D. Hoyer</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neuroscience Research, Novartis Institutes for BioMedical Research</s1>
<s2>4002 Basel</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>4002 Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L." last="Gregoire">L. Gregoire</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Genomic Research Center, Centre Hospitalier Universitaire de Québec (CHUQ), Pavilion CHUL and Faculty of Pharmacy, Laval University</s1>
<s2>QC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Genomic Research Center, Centre Hospitalier Universitaire de Québec (CHUQ), Pavilion CHUL and Faculty of Pharmacy, Laval University</s1>
<s2>QC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gasparini, F" sort="Gasparini, F" uniqKey="Gasparini F" first="F." last="Gasparini">F. Gasparini</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neuroscience Research, Novartis Institutes for BioMedical Research</s1>
<s2>4002 Basel</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>4002 Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gomez Mancilla, B" sort="Gomez Mancilla, B" uniqKey="Gomez Mancilla B" first="B." last="Gomez-Mancilla">B. Gomez-Mancilla</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neuroscience Research, Novartis Institutes for BioMedical Research</s1>
<s2>4002 Basel</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>4002 Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Genomic Research Center, Centre Hospitalier Universitaire de Québec (CHUQ), Pavilion CHUL and Faculty of Pharmacy, Laval University</s1>
<s2>QC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuroscience</title>
<title level="j" type="abbreviated">Neuroscience</title>
<idno type="ISSN">0306-4522</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuroscience</title>
<title level="j" type="abbreviated">Neuroscience</title>
<idno type="ISSN">0306-4522</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AMPA receptor</term>
<term>Cabergoline</term>
<term>Dopamine</term>
<term>Glutamate</term>
<term>Levodopa</term>
<term>Monkey</term>
<term>Neurotoxin</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Récepteur AMPA</term>
<term>Neurotoxine</term>
<term>Lévodopa</term>
<term>Glutamate</term>
<term>Cabergoline</term>
<term>Dopamine</term>
<term>Maladie de Parkinson</term>
<term>Singe</term>
<term>MPTP</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Overactivity of glutamate neurotransmission is suspected to be implicated in Parkinson's disease and levodopa-induced dyskinesia. The fast glutamatergic transmission in the striatum from the cortex is mediated mainly by non-N-methyl-D-aspartate (non-NMDA) receptors. Animal models of Parkinson's disease reveal conflicting data concerning striatal glutamate AMPA receptors. The present study thus sought to shed light on the relationship of striatal AMPA receptors to the development of levodopa-induced dyskinesia. [<sup>3</sup>
H]Ro 48-8587, a highly potent and selective-specific antagonist ligand for AMPA receptors, was used to investigate, by autoradiography, striatal AMPA receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys treated for 1 month with levodopa alone, levodopa+CI-1041 (NMDA receptor antagonist) or levodopa+cabergoline (D2 receptor agonist). Levodopa-treated MPTP monkeys developed dyskinesias while those that received levodopa+CI-1041 or levodopa+cabergoline did not. In the anterior caudate nucleus and putamen, specific binding of [<sup>3</sup>
H]Ro 48-8587 was reduced in all MPTP-treated monkeys compared to control monkeys, but no significant effect of MPTP was measured in the posterior striatum. In dyskinetic monkeys, specific binding of [<sup>3</sup>
H]Ro 48-8587 was elevated in subregions of the posterior caudate nucleus and putamen as compared to saline-treated MPTP monkeys. Levodopa+CI-1041 treatment left unchanged specific binding of [<sup>3</sup>
H]Ro 48-8587 whereas levodopa+cabergoline treatment reduced it in subregions of the posterior caudate nucleus and putamen compared to control and levodopa-treated MPTP monkeys. Specific binding of [<sup>3</sup>
H]Ro 48-8587 was low in the globus pallidus and remained unchanged following both lesion and treatments. In conclusion, the elevated values of AMPA receptors in dyskinetic monkeys (and their prevention through treatments) were only observed in subregions of the striatum.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>Suisse</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Ouattara, B" sort="Ouattara, B" uniqKey="Ouattara B" first="B." last="Ouattara">B. Ouattara</name>
</noRegion>
<name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L." last="Gregoire">L. Gregoire</name>
<name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
</country>
<country name="Suisse"><noRegion><name sortKey="Hoyer, D" sort="Hoyer, D" uniqKey="Hoyer D" first="D." last="Hoyer">D. Hoyer</name>
</noRegion>
<name sortKey="Gasparini, F" sort="Gasparini, F" uniqKey="Gasparini F" first="F." last="Gasparini">F. Gasparini</name>
<name sortKey="Gomez Mancilla, B" sort="Gomez Mancilla, B" uniqKey="Gomez Mancilla B" first="B." last="Gomez-Mancilla">B. Gomez-Mancilla</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D36 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D36 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:10-0396916
   |texte=   CHANGES OF AMPA RECEPTORS IN MPTP MONKEYS WITH LEVODOPA-INDUCED DYSKINESIAS
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

CHANGES OF AMPA RECEPTORS IN MPTP MONKEYS WITH LEVODOPA-INDUCED DYSKINESIAS

CHANGES OF AMPA RECEPTORS IN MPTP MONKEYS WITH LEVODOPA-INDUCED DYSKINESIAS

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri